Anistreplase
| Clinical data | |
|---|---|
| Trade names | Eminase |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Pharmacokinetic data | |
| Biological half-life | 90 minutes |
| Identifiers | |
| CAS Number | 81669-57-0  |
| ATC code | B01AD03 (WHO) |
| DrugBank | DB00029 |
| KEGG | D02947 |
| Chemical data | |
| Molecular mass | approx. 131 kg/mol |
| (verify) | |
Anistreplase is a thrombolytic drug.[1][2][3]
Anistreplase has been developed by Beecham as Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC)
Mechanism
It is a complex of purified human plasminogen and bacterial streptokinase that has been acylated to protect the enzyme's active site. When the drug is administered, the acyl group gets hydrolyzed, thereby freeing the activator complex. It converts plasminogen to plasmin, which in turn degrades fibrin (blood clots) to fibrin split products.
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." /><templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
